Gain Therapeutics (NASDAQ:GANX) Given New $7.00 Price Target at Maxim Group

Gain Therapeutics (NASDAQ:GANX) had its price objective increased by Maxim Group from $5.00 to $7.00 in a research note published on Tuesday morning, Marketbeat Ratings reports. Maxim Group currently has a buy rating on the stock.

A number of other brokerages have also issued reports on GANX. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a research report on Thursday, July 3rd. BTIG Research restated a “buy” rating and set a $9.00 target price on shares of Gain Therapeutics in a research report on Monday, September 8th. Roth Capital decreased their target price on shares of Gain Therapeutics from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, August 13th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Saturday, September 27th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Gain Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $7.86.

Gain Therapeutics Trading Down 9.0%

Shares of GANX opened at $2.02 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.79 and a quick ratio of 1.79. The firm has a 50 day simple moving average of $1.73 and a 200-day simple moving average of $1.79. Gain Therapeutics has a 1-year low of $1.41 and a 1-year high of $3.19. The stock has a market cap of $72.62 million, a price-to-earnings ratio of -3.21 and a beta of 0.11.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). Equities analysts forecast that Gain Therapeutics will post -1 EPS for the current fiscal year.

Hedge Funds Weigh In On Gain Therapeutics

Large investors have recently bought and sold shares of the stock. Kovitz Investment Group Partners LLC purchased a new position in Gain Therapeutics during the first quarter worth approximately $91,000. Dauntless Investment Group LLC purchased a new position in Gain Therapeutics during the first quarter worth approximately $240,000. Marshall Wace LLP raised its stake in shares of Gain Therapeutics by 41.0% in the 2nd quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock valued at $498,000 after acquiring an additional 80,407 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Gain Therapeutics by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after acquiring an additional 8,251 shares during the period. Hedge funds and other institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.